JASN:糖尿病肾病的新生物标记物

2017-05-08 MedSci medicalxpress

2型糖尿病的常见并发症发生在肾小球的过滤作用受损时,导致尿液中蛋白质的异常积累和肾功能的下降。这种称为糖尿病肾病的病症可能导致目前难以预测的不可逆的肾衰竭。西奈山的伊坎健康学院医学教授Chirag Parikh领导的研究小组进行了一项研究最近取得了进展,这将有助于改善这种疾病的诊断和治疗方案。

2型糖尿病的常见并发症发生在肾小球的过滤作用受损时,导致尿液中蛋白质的异常积累和肾功能的下降。这种称为糖尿病肾病的病症可能导致目前难以预测的不可逆的肾衰竭。西奈山的伊坎健康学院医学教授Chirag Parikh领导的研究小组进行了一项研究最近取得了进展,这将有助于改善这种疾病的诊断和治疗方案。

为了评估这些生物标记物,该研究小组进行了早期随机对照试验,控制糖尿病心血管危险行动研究(ACCORD)和晚期退伍军人糖尿病实验研究(VANEPHRON-D)。测量了来自两个大型联邦资助临床试验样本中糖尿病患者血液中的三种特异性蛋白(TNFR-1,TNFR-2和KIM-1)。他们测试这些蛋白质是否与肾脏滤过功能的下降有关。

结果显示,在基线水平时,NEPHRON-D晚期糖尿病肾病(DKD)人群的TNFR-1,TNFR-2和KIM-1的中位浓度比ACCORD早期DKD人群的浓度大约高出两倍。在两项研究中,到达肾病的患者的基线水平高于那些没有达到这个结果的患者。TNFR-1,TNFR-2和KIM-1水平翻倍与肾病风险之间的关系在两组研究中都具有显着差异。在NEPHRON-D的临床中,将这些生物标记物纳入临床模型中,肾病变率从0.68(0.02)增加到0.75(0.02)。此外,系统的文献综述表明在DKD中,这些炎症因子和肾病变之间高度相关。与早期和晚期糖尿病肾病患者相比,每种蛋白质与肾功能下降的风险独立相关。

这些结果显示,这些蛋白质作为生物标志物在预测糖尿病患者肾脏疾病进展的方面以及评估疾病治疗在临床试验中的功效具有潜在作用。

原文出处:Steven G. Coca et al. Plasma Biomarkers and Kidney Function Decline in Early and Established Diabetic Kidney Disease, Journal of the American Society of Nephrology (2017).

此文系梅斯医学(MedSci)原创编译整理,转载须授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1904464, encodeId=8af6190446485, content=<a href='/topic/show?id=b8aa619690e' target=_blank style='color:#2F92EE;'>#标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61969, encryptionId=b8aa619690e, topicName=标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Wed Mar 14 18:00:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941312, encodeId=d9c819413129c, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Sat Oct 07 19:00:00 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345347, encodeId=0e75134534e73, content=<a href='/topic/show?id=8907693e0fa' target=_blank style='color:#2F92EE;'>#生物标记#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69370, encryptionId=8907693e0fa, topicName=生物标记)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=278f2500221, createdName=12498fa0m11暂无昵称, createdTime=Wed May 10 12:00:00 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349921, encodeId=be61134992128, content=<a href='/topic/show?id=3a59693e129' target=_blank style='color:#2F92EE;'>#生物标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69371, encryptionId=3a59693e129, topicName=生物标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed May 10 12:00:00 CST 2017, time=2017-05-10, status=1, ipAttribution=)]
    2018-03-14 wjywjy
  2. [GetPortalCommentsPageByObjectIdResponse(id=1904464, encodeId=8af6190446485, content=<a href='/topic/show?id=b8aa619690e' target=_blank style='color:#2F92EE;'>#标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61969, encryptionId=b8aa619690e, topicName=标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Wed Mar 14 18:00:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941312, encodeId=d9c819413129c, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Sat Oct 07 19:00:00 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345347, encodeId=0e75134534e73, content=<a href='/topic/show?id=8907693e0fa' target=_blank style='color:#2F92EE;'>#生物标记#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69370, encryptionId=8907693e0fa, topicName=生物标记)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=278f2500221, createdName=12498fa0m11暂无昵称, createdTime=Wed May 10 12:00:00 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349921, encodeId=be61134992128, content=<a href='/topic/show?id=3a59693e129' target=_blank style='color:#2F92EE;'>#生物标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69371, encryptionId=3a59693e129, topicName=生物标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed May 10 12:00:00 CST 2017, time=2017-05-10, status=1, ipAttribution=)]
    2017-10-07 chenhongpeng
  3. [GetPortalCommentsPageByObjectIdResponse(id=1904464, encodeId=8af6190446485, content=<a href='/topic/show?id=b8aa619690e' target=_blank style='color:#2F92EE;'>#标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61969, encryptionId=b8aa619690e, topicName=标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Wed Mar 14 18:00:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941312, encodeId=d9c819413129c, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Sat Oct 07 19:00:00 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345347, encodeId=0e75134534e73, content=<a href='/topic/show?id=8907693e0fa' target=_blank style='color:#2F92EE;'>#生物标记#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69370, encryptionId=8907693e0fa, topicName=生物标记)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=278f2500221, createdName=12498fa0m11暂无昵称, createdTime=Wed May 10 12:00:00 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349921, encodeId=be61134992128, content=<a href='/topic/show?id=3a59693e129' target=_blank style='color:#2F92EE;'>#生物标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69371, encryptionId=3a59693e129, topicName=生物标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed May 10 12:00:00 CST 2017, time=2017-05-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1904464, encodeId=8af6190446485, content=<a href='/topic/show?id=b8aa619690e' target=_blank style='color:#2F92EE;'>#标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61969, encryptionId=b8aa619690e, topicName=标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Wed Mar 14 18:00:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941312, encodeId=d9c819413129c, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Sat Oct 07 19:00:00 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345347, encodeId=0e75134534e73, content=<a href='/topic/show?id=8907693e0fa' target=_blank style='color:#2F92EE;'>#生物标记#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69370, encryptionId=8907693e0fa, topicName=生物标记)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=278f2500221, createdName=12498fa0m11暂无昵称, createdTime=Wed May 10 12:00:00 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349921, encodeId=be61134992128, content=<a href='/topic/show?id=3a59693e129' target=_blank style='color:#2F92EE;'>#生物标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69371, encryptionId=3a59693e129, topicName=生物标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed May 10 12:00:00 CST 2017, time=2017-05-10, status=1, ipAttribution=)]

相关资讯

多学科综合干预或可改善糖尿病肾病预后

《Journal of Diabetes and Its Complications》2017年3月1日发表的一项为期2年的随机对照研究中,作者招募了合并3~4期慢性肾脏病的2型糖尿病患者,旨在评估糖尿病肾病门诊多学科诊治方法的有效性,干预方式包括饮食、行为和药物。研究结果显示,与标准治疗组相比,干预治疗组患者进展至终末期肾病(ESRD)风险显著下降。并且,干预治疗组的HbA1c、血脂和血压控制情

EASD 2016:中国证据——糖尿病肾病基因位点新发现

会议快讯糖尿病肾病是糖尿病患者死亡的主要原因之一。流行病学调查显示,亚洲糖尿病患者糖尿病肾病(DKD)负担沉重。但是人们对于糖尿病肾病的遗传基础仍然所知甚少。2016年EASD年会上,来自中国香港的马青云(R.C. Ma)教授分享了通过全基因组关联分析(GWAS),在中国2型糖尿病患者中识别到的终末期肾病(ESRD)相关基因位点,拓展了对中国2型糖尿病患者肾病的遗传学认识。1糖尿病心-肾并发症

Diabetes Care:氯沙坦能否延缓糖尿病肾病的进展?

目的:评估早期服用氯沙坦能都延缓糖尿病肾病的进展。 方法:研究者对169名美国印第安人进行了长达6年的研究,所有患者为2型糖尿病,尿白蛋白/肌酐比值<300 mg/g;其中84名患者被随机分配到氯沙坦组,余下85名患者为安慰剂对照组。 主要终点为肾小球滤过率(GFR;碘酞酸盐)下降到≤60 mL/min,或基线GFR值下降一半(对于基线GFR <120 mL/min的患者)。

盘点:近期糖尿病肾病研究进展汇总

在发达国家,糖尿病已是导致慢性肾脏病的主要病因,在发展中国家,糖尿病正逐渐成为慢性肾脏病的主要致病原因。糖尿病合并慢性肾脏病也是我国糖尿病研究和治疗领域面临的重大问题。本文梅斯医学小编就糖尿病肾病相关研究进展进行汇总,与大家分享。【1】JAMA:1988-2014年间美国成人糖尿病患者肾病的变化糖尿病肾病是导致美国及世界上慢性和终末期肾脏疾病的首要原因。人口统计学和治疗的变化可能会影响糖尿病肾

参芪地黄汤联合缬沙坦治疗气阴两虚型早期糖尿病肾病的临床疗效

广东鹤山市中医院内科采用参芪地黄汤联合缬沙坦治疗气阴两虚型早期糖尿病肾病多年来临床效果显著,可改善中医症候,切不良反应率较低。

Diabetologia:一种抗衰老激素Klotho有助诊治糖尿病肾病

英国研究人员在新一期德国《糖尿病学》期刊上报告说,他们对Ⅰ型糖尿病病人的研究发现,人体内一种抗衰老激素的水平与早期糖尿病肾病相关,未来或可用于预测糖尿病肾病发病风险以及开发新疗法。